Middle East and Africa Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others), Industry Trends and Forecast to 2029
Market Analysis and Insights
The Food and Drug Administration (FDA) approved three clinical drugs: buprenorphine, methadone, and naltrexone. Medication-assisted treatment (MAT) is applied to cure alcohol use disorder, opioid dependency medication, and opioid overdose prevention medication. Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop alcohol use despite adverse social, occupational, or health consequences. Acamprosate, disulfiram, and naltrexone are the most common medications used to treat alcohol use disorder (AUD). The opioid dependency medication, rise in addiction for opioids among patients. Buprenorphine, methadone and naltrexone are used to treat opioid use disorders to short-acting opioids such as heroin, morphine, and codeine, as well as semi-synthetic opioids like oxycodone and hydrocodone. These MAT medications are safe for months, years, or even a lifetime.
Market Definition
Medication-assisted treatment (MAT) involves using medications, combined with counselling and behavioural therapies, to provide a complete patient approach for the treatment of substance use disorders. MAT is primarily used to treat addiction to opioids such as heroin and prescription pain relievers. For opioid overdose prevention medication, naloxone is used to prevent opioid overdose by reversing the toxic effects of the overdose. According to the World Health Organization (WHO) and Substance Abuse and Mental Health Services Administration (SAMHSA) naloxone is one of many medications considered essential to a functioning health care system.
In the Middle East and Africa medication-assisted treatment is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the medication-assisted treatment (MAT) market will grow at a CAGR of 7.1% from 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others)
|
|
Countries Covered
|
South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait and Rest of Middle East and Africa.
|
|
Market Players Covered
|
Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Pfizer Inc., Glenmark Pharmaceutical Inc., Viatris Inc., VistaPharm, Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC. among others
|
Middle East and Africa Medication-Assisted Treatment (MAT) Market Dynamics
Drivers
- The Rise In The Incidence Of Opioid Use Disorders (Opioid Dependency Medication)
Medication-assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies to provide a "whole-patient" approach to treating substance use disorders. Medications used in MAT are approved by the Food and Drug Administration (FDA), and MAT programs are clinically driven and tailored to meet each patient's needs.
For instance,
- The prevalence of high-risk opioid use (by injection or long duration/regular use) among adults (aged 15–64) in Middle East and Africa has been relatively stable for many years, with estimates of users standing at around 0.35 % of the EU population
As the companies are constantly engaged in research and developmental activities, the knowledge about the incidence of alcohol use disorder and opioid use disorders would help in finding novel solutions and that would aid in more collaborations and partnerships with market players in countries such as the U.S., Europe, and Asia-Pacific region. This signifies the increase in research and development-related investments for initiating generic medications in medication-assisted treatment (MAT), which is expected to boost the market growth.
- Use Of Reimbursement For Medication-Assisted Treatment (MAT)
Reimbursement may be available for medication-assisted treatment even if the medication does not have a valid status. If the medication does not have preferred level, the prescriber must obtain permission from the member's pharmacy benefit plan.
For instance,
- In February 2021, The American College of Emergency Physicians (ACEP) had developed the Reimbursement & Coding FAQs and Pearls for informational purposes on medication-assisted treatment
Extensive research accentuates that medications used in MAT are effective for the treatment of alcohol and opioid use disorders and that naloxone is effective for addressing acute opioid overdose. As Medicaid programs continue to assess the need of individuals with alcohol and opioid use disorders in their states, this report can be a resource. Thus, this signifies the benefit of reimbursement coverage by Medicaid, which is expected to boost the growth of the global medication-assisted treatment (MAT) market.
Opportunities
- Strategic Initiative By Market Players
The demand for medication-assisted treatment has increased in the U.S., Middle East, and Africa owing to the timely treatment of chronic conditions. These favourable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.
For instance,
- In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations
These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity that is helping them to drive market growth.
Restraints/Challenges
- Side Effects Of Drugs Used In Medication-Assisted Treatment (MAT)
Medication-assisted treatment (MAT) involves using medications collated with counseling and behavioural therapies to provide a "whole-patient" approach as part of the comprehensive treatment strategy. Therefore, the present high cost is expected to show a descending trend. MAT is most effective for treating alcohol and opioid use disorders. However, specific side effects have been reported.
For instance,
- Methadone and buprenorphine, the generic medications, are chemically similar to opioids, so their side effects can be similar too. These may include constipation, drowsiness, and dizziness. Some people may experience more severe side effects
The adverse complications reported would lead to a decline in sales of the medicated opioid dependency medications, which would limit the sales of the medicines. In addition, it would affect the reliability of manufacturers involved in this market and hence be expected to restrain the market growth.
The Medication-assisted treatment (MAT) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the medication-assisted treatment (MAT) market contact Data Bridge Market Research for an Analyst Brief. Our team will help you take an informed market decision to achieve market growth.
Covid-19 Impact on the Medication-Assisted Treatment (MAT) Market
During the pandemic, medication-assisted treatment remarkably reduces mortality and morbidity of patients with COVID-19. Further large-scale studies are needed to approve these results. A protocol for medication-assisted treatment in COVID-19 infection should be defined to achieve the best possible clinical outcomes. Clinical trials were conducted during Covid-19 Medication for opioid use disorder (MOUD) services are key to addressing the opioid crisis, and COVID-19 has significantly impacted MOUD delivery.
Recent Development
- In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations
Middle East and Africa Medication-Assisted Treatment (MAT) Market Scope
The medication-assisted treatment (MAT) market is segmented on the basis of eight segments: type, products, drug type, dosage form, route of administration, population type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Medication
- Therapy
On the basis of type the Middle East and Africa medication-assisted treatment (MAT) market is segmented into medication and therapy.
Products
- Buprenorphine and Naloxone
- Naltrexone
- Buprenorphine
- Methadone
- Naloxone
- Disulfiram
- Acamprosate
On the basis of products, the Middle East and Africa medication-assisted treatment (MAT) market is segmented into buprenorphine and naloxone, naltrexone, buprenorphine, methadone, naloxone, disulfiram and acamprosate.
Drug Type
- Generics
- Branded
On the basis of drug type, the Middle East and Africa medication-assisted treatment (MAT) market is segmented into generics and branded.
Dosage Form
- Immediate Release
- Extended Release
On the basis of dosage form, the Middle East and Africa medication-assisted treatment (MAT) market is segmented into immediate release and extended release.
Route of Administration
- Oral
- Parenteral
- Others
On the basis of route of administration, the Middle East and Africa medication-assisted treatment (MAT) market is segmented into oral, parenteral and others.
Population Type
- Adults
- Teenage
On the basis of population type, the Middle East and Africa medication-assisted treatment (MAT) market is segmented into adults and teenage.
End User
- Rehabilitation Clinics
- Hospitals
- Specialty Centers
- Homecare
- Others
On the basis of end user, the Middle East and Africa medication-assisted treatment (MAT) market is segmented into rehabilitation clinics, hospitals, speciality centres, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Direct Tender
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the Middle East and Africa medication-assisted treatment (MAT) market is segmented into hospital pharmacy, direct tender, retail pharmacy, online pharmacy and others.
Medication-Assisted Treatment (MAT) Market Regional Analysis/Insights
The Middle East and Africa medication-assisted treatment (MAT) market is analysed market size insights and trends are provided by regions, product type, type, application, workflow, end user and distribution channel as referenced above.
The countries covered in the medication-assisted treatment (MAT) market report are South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait and the Rest of Middle East and Africa.
South Africa is expected to dominate the market due to lack of awareness about substance use disorders and the rise in the population receiving medication-assisted treatment (MAT) and medication-assisted awareness programs medication-assisted treatment (MAT) in the Middle East and Africa region.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future market trends. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the significant pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Medication-Assisted Treatment (MAT) Market Share Analysis
The Middle East and Africa medication-assisted treatment (MAT) market competitive landscape provides competitors' details. Components included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the medication-assisted treatment (MAT) market.
Some of the major players operating in the medication-assisted treatment (MAT) market are Indivior PLC, Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Pfizer Inc., Glenmark Pharmaceutical Inc., Viatris Inc., Alvogen, Accord Healthcare, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd.Amneal Pharmaceuticals LLC. among others.
SKU-